Amorphous solid dispersions enhanced release performance of enantiopure praziquantel, suggesting a potential clinical benefit over the racemic form.
ASDs of ( R , S )-PZQ and ( R )-PZQ were tested in various media. HPMCAS effectively inhibited crystallization, and ( R )-PZQ-HPMCAS showed good release performance. An ASD of ( R )-PZQ may provide a good clinical alternative to the racemic drug.
No takes yet. Share an insight, caveat, or question.
Alvarenga et al. (2025) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: